Raltegravir

Generic Name: Raltegravir

Brand Names: Isentress

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁FN_₆O_₅

CAS Number: 518048-05-0

Unique Ingredient Identifier: 22VKV8053U

Background: Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.

Indication: For the treatment of HIV-1 infection in conjunction with other antiretrovirals.

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: Post-exposure prophylaxis for occupational exposure to HIV therapy

Clinical Trials

Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients

Not Applicable

Completed

Conditions: HIV Infections

Interventions: Drug: raltegravir

First Posted Date: 2008-05-06

Last Posted Date: 2013-07-05

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 18

Registration Number: NCT00672932

Locations: 🇺🇸
Ucsf Ccrc, Sfgh, San Francisco, California, United States

Raltegravir as Early Therapy in African-Americans Living With HIV Study

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Raltegravir + Truvada

First Posted Date: 2008-04-28

Last Posted Date: 2017-03-03

Lead Sponsor: David A Wohl, MD

Target Recruit Count: 38

Registration Number: NCT00667433

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸
The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: Maraviroc
Drug: Raltegravir

First Posted Date: 2008-04-25

Last Posted Date: 2013-01-25

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 18

Registration Number: NCT00666705

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

The Influence of Raltegravir on Pravastatin Pharmacokinetics(GRAPPA)

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Pravastatin and raltegravir
Drug: Pravastatin
Drug: Raltegravir

First Posted Date: 2008-04-24

Last Posted Date: 2020-10-19

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 24

Registration Number: NCT00665717

Locations: 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands

Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy

Not Applicable

Completed

Conditions: HIV Infections
AIDS

Interventions: Drug: raltegravir
Drug: efavirenz

First Posted Date: 2008-04-21

Last Posted Date: 2017-05-30

Lead Sponsor: University of California, Davis

Target Recruit Count: 25

Registration Number: NCT00661960

Locations: 🇺🇸
CARES Clinic, Sacramento, California, United States
🇺🇸
UC Davis Medical Center, Sacramento, California, United States

Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Raltegravir
Drug: Emtricitabine/tenofovir disoproxil fumarate

First Posted Date: 2008-04-18

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 40

Registration Number: NCT00660972

Locations: 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸
IHV Baltimore Treatment CRS, Baltimore, Maryland, United States
🇺🇸
Ohio State University CRS, Columbus, Ohio, United States

and more 12 locations

Raltegravir Therapy for Women With HIV and Fat Accumulation

Phase 2

Completed

Conditions: Lipodystrophy
HIV Infections

Interventions: Drug: raltegravir

First Posted Date: 2008-04-10

Last Posted Date: 2012-12-19

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 39

Registration Number: NCT00656175

Locations: 🇨🇦
University Health Network, Toronto, Toronto, Ontario, Canada
🇺🇸
Case School of Medicine, Cleveland, Ohio, United States
🇺🇸
UCLA CARE Center, Los Angeles, California, United States

and more 2 locations

Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: Raltegravir and emtricitabine/tenofovir
Drug: Raltegravir & Lopinavir/ritonavir

First Posted Date: 2008-04-07

Last Posted Date: 2015-08-03

Lead Sponsor: Margaret A. Fischl, M.D.

Target Recruit Count: 44

Registration Number: NCT00654147

Locations: 🇺🇸
University of Miami AIDS Clinical Research Unit, Miami, Florida, United States

Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals

Phase 4

Terminated

Conditions: HIV Infections

Interventions: Drug: Lopinavir/Ritonavir
Drug: Raltegravir
Drug: Truvada

First Posted Date: 2008-03-11

Last Posted Date: 2018-08-29

Lead Sponsor: George Washington University

Target Recruit Count: 6

Registration Number: NCT00632970

Locations: 🇺🇸
George Washington University Medical Faculty Associates, Washington, District of Columbia, United States

Raltegravir Intensification in HIV-infected Patients

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: Placebo
Drug: Raltegravir

First Posted Date: 2008-03-07

Last Posted Date: 2020-08-17

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 30

Registration Number: NCT00631449

Locations: 🇺🇸
San Francisco General Hospital, Clinical Research Center, San Francisco, California, United States
🇺🇸
San Francisco Veterans Affairs Medical Center, San Francisco, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy